Menú
Professional & Student Poster Presentations
Professional
- P01: A COVID-19 Epidemiologic Model to Enhance Efficiency Through Evidence-Based Site Selection for Vaccine and Treatment Trials
- P02: A Novel Partner Communication Gateway (PCG) to Enable Data Exchange and Reduce Operational Burden
- P03: A Quantitative and Metrics Driven Framework For Maximizing Data Utility While Balancing Re-Identification Risk
- P04: A Retrospective Regulatory Review: Leveraging Safety to Inform and Encourage Diverse and Inclusive Clinical Trial Enrollment
- P05: A Review of Problems with Pharmacovigilance Programs and Biologics
- P06: A Systematic Review of Health Utility Values for Immunotherapy-Related Adverse Events
- P07: A Unique Use of Real-World Data in a Complex Private-Public Collaborative Partnership to Support a New Drug Application
- P08: Accelerated Decision Making with Analytical Solutions: Case Studies
- P09: Age Did Not Impact Participants’ Ease of Use for Reporting Their SARS-CoV-2 Symptoms in an Electronic Diary: Obvio-19 Results
- P10: An Automated, Scalable Data Monitoring Tool for Proactive Safety Quality Assurance
- P11: Applying Natural Language Processing to the Extraction of Medical Safety Information from Free-Text on the CIOMS Form
- P12: Are Innovative Formats of Communicating Medical Information Appealing to Healthcare Professionals?
- P13: Are you Really Listening? Find New and Innovative Ways to Capture the Patient Voice and Translate into Insights
- P14: Automatic Image Segmentation to Preprocess Pediatric Stool Photos
- P15: Bayesian Prognostic Covariate Adjustment: a Method to Reduce Sample Sizes While Maintaining Power and Statistical Accuracy
- P16: Best Practices: Keys Steps to Maintaining TMF Inspection-Readiness
- P18: COVID-19 Self-Isolation Measures Seriously Impacted Quality of Medical Care for People Living with Chronic Conditions
- P19: COVID-19 Treatment Patterns in the Real-World Hospital Setting
- P20: Designing and Implementing a Product Labeling Utility to Support Medical Assessment of Adverse Events
- P21: Development and Experience with a Global Medical Information Vaccine Stability Chatbot
- P22: Development of a Composite Mortality Score Addresses Racial Bias in Mortality Data Reporting
- P23: Development of an Error Prevention System for Patient-Reported Outcome Measures: A Pilot Study
- P24: Digital Risk Minimization Tools: Implementation Challenges and Strategies for Successful Uptake
- P25: Digital Transformation of the Drug Development Workforce
- P26: Discrepancies Between the Labels of Originator and Generic Pharmaceutical Products: Implications for Patient Safety
- P27: Diversity in Clinical Research: Portfolio of Solutions to Broaden Access for Expanded Racial and Ethnic Representation
- P28: Educational, Gender, and Age Diversity in the Corporate Leadership of Fortune 500 Pharmaceutical Companies: A 3-Year Update
- P29: Enhancing Compliance and Improving Oversight of Additional Risk Minimization Measures by Redesigning the Process
- P30: Establishing Representative Pediatric Liver Enzymes Reference Ranges Utilizing United States Optum® Real World Data
- P31: Estimation Of Causal Effect In Integrating Randomized Clinical Trial And Observational Data
- P32: Evaluation of the Clinical Impact of Rare Disease Scientific Responses Provided by Pfizer US Medical Information to Providers
- P33: Evolving Trends in Medical Affairs in the Pharmaceutical Industry: Plain Language Summaries of Scientific Publications
- P34: Facilitated Regulatory Pathways (FRPs): Their Value and How it Could be Maximized to Ensure Timely Availability of Medicines
- P35: FDA Postmarketing Requirements in Pregnant and Lactating Women: Past, Present, and Future
- P36: How to Study the Effect of the Duration of Treatment Using Real-World Data: A Case Study Using Breast Cancer Screening
- P37: Identification, Data Collection, and Medical Analysis of COVID-19 Cases Reported within Interventional Clinical Trials
- P38: Impact of A Cloud-Based Clinical Data Management System on COVID-19 Trials: Rapid Operationalization of a Remote Approach
- P39: Impact of ISO IDMP on the Pharmaceutical Industry and Preparation to Comply
- P40: Increasing Efficiency and Cost-Effectiveness by Automating the Authoring of Aggregate Reports
- P42: In-Person Versus Remote Clinical Trial Activities: The Evolving Landscape and Patient Preferences
- P43: Key Considerations for Patient-Centric Decentralized Trials
- P44: Knowledge and Perception of Gene Therapy among Spanish Speaking Patients and Caregivers in the Bleeding Disorders Community
- P46: Linking Diverse Clinical Trial and Real-World Data Sets to Enable Clinical Research in a Post Covid-19 World
- P47: Making consent relevant to patients
- P48: Medical Information Product Launch Best Practices During COVID-19: Journey from Emergency Use Authorization to Approval
- P49: Mid-Urethral Slings for Stress Urinary Incontinence: Effectiveness and Adverse Events Using Real-World Data
- P51: Opportunities for Patient Engagement to Help Mitigate Research and Development Risk
- P52: Patient Engagement in Cell Therapy and Gene Therapy Clinical Trials
- P53: Patient Preferences for Clinical Trial Study Engagement
- P54: Patient Safety Integration Framework Between Two Major Biopharmaceutical Organizations
- P56: Performance of Project Orbis and the Real Time Oncology Review (RTOR) Pilot Program
- P57: Presentation of Safety Risks Throughout the Product Lifecycle
- P58: Proactive/Prospective Feasibility Studies to Identify Rare Disease Patients for Clinical Trials
- P59: Prognostic Covariate Adjustment (PROCOVA) Decreases Uncertainty in Randomized Trials, Enabling Smaller Sample Sizes.
- P60: Putting the “World” into Real World Evidence: The Evolving Global Landscape of RWE Regulatory Frameworks
- P61: Race and Diurnal Variability of Biomarkers for Diabetes and Cardiovascular Disease
- P62: Regulatory Considerations for Drug Development in Metastatic Gastric Cancer
- P63: Safety Gateway Reconciliation Tool
- P64: Safety Initiative for Multi-Drug Regimens: Guiding Principles for Identification, Management, and Reporting of Safety Issues
- P66: Speed Up Inspection Readiness with Analytical Solutions
- P68: The Use of CPP for Drug Registration Processes in Twenty Five Countries in the Americas: Requirements and Areas of Opportunity
- P69: The Value of An Online Destination in Tardive Dyskinesia in Educating Practicing Clinicians
- P70: Time to Clinical Guidance Inclusion of Orphan Drugs After Expedited Approval
- P71: Toolkits to help amplify the patient voice in clinical research
- P72: Trends in the Use of Novel Trial Design Master Protocols in Clinical Research
- P73: Utilizing Community-Based EHR Data Systems to Identify Liver Disease Risk in Female Patients
Student
- S01: A Comparative Study of Government Responses to COVID-19: Mainland China and 8+2 Representative Countries
- S02: An Evaluation of Trust-Building Measures Within Pharmaceutical Brand Websites in Comparison to a Social Media Trust Analysis
- S03: Assessing the Need for Therapeutic Innovation in Muscle Cramp Treatments
- S05: Benefits of Risk-Based Monitoring of Investigator-Initiated Trials (IITs) in an Academic Setting
- S06: Breaking Barriers: Identifying Access Obstacles to Diabetes Technology in Low-Income, Type 1 Diabetic Patients
- S07: Building an Innovative, Comprehensive Plain Language Summary Development Platform
- S08: Characteristics of Special Regulatory Pathways Used to Authorize COVID-19 Vaccines in Latin America
- S09: Chronically Left Out: Lack of Patient Diversity in Chronic Disease Clinical Trials in Los Angeles
- S10: Communication Strategies to Boost COVID-19 Vaccine Compliance
- S11: Does China TCM Hospitals Provide Efficient Healthcare to the Nation? Empirical DEA Modeling Study from 2013 to 2018
- S12: Gender Differences of the Intention, Attitude, and Behaviour of Job Searching Among Final-Year Pharmacy Undergraduate Students
- S13: Health Communication Promotes Compliance to Coronavirus 2019 (COVID-19) Through Plain Language
- S14: Impact of the COVID-19 Pandemic on Telehealth
- S15: Inclusion of Pediatric Participants in Clinical Trials: Which Regulatory Process is Better, BPCA or NDA?
- S16: Is Clinical Trial Design a Barrier to Alzheimer’s Disease Pharmacotherapy Development? An Analysis Based on Drug Class
- S17: Literature Review on Medical Science Liaison Key Performance Indicators and Best Practices
- S18: Patterns of Exclusion: Antidepressant Clinical Trial Comorbidities
- S20: Regulatory and Compliance Challenges of Dietary Supplements in the A`reas of Quality and Therapeutic Claims
- S21: Review of Government-Sponsored Studies and Food and Drug Administration (FDA) Guidance for COVID-19 Diagnostic Testings
- S23: Suggestion on Pharmaceutical Care Based on Glucocorticoid-Related Medical Damage Disputes
- S24: Youth Nicotine Addiction: Strategic Regulation Defiance by the Disposable Electronic Nicotine Delivery System (ENDS) Industry